AAAAAA

   
Results: 1-10 |
Results: 10
Environmental risk factors for amyotrophic lateral sclerosis
Authors: Armon, C
Citation: C. Armon, Environmental risk factors for amyotrophic lateral sclerosis, NEUROEPIDEM, 20(1), 2001, pp. 2-6
Oxandrolone in ALS: Preliminary analysis - General discussion
Authors: Appel, S Rosenfeld, J Donofrio, P Brooks, B Tandan, R Pioro, E Armon, C Johnston, W
Citation: S. Appel et al., Oxandrolone in ALS: Preliminary analysis - General discussion, AMYOTROPH L, 1, 2000, pp. 25-26
Alzheimer's disease underlies some cases of complex partial status epilepticus - Clinical, radiologic, EEG, and pathologic correlations
Authors: Armon, C Peterson, GW Liwnicz, BH
Citation: C. Armon et al., Alzheimer's disease underlies some cases of complex partial status epilepticus - Clinical, radiologic, EEG, and pathologic correlations, J CL NEURPH, 17(5), 2000, pp. 511-518
Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis
Authors: Armon, C Graves, MC Moses, D Forte, DK Sepulveda, L Darby, SM Smith, RA
Citation: C. Armon et al., Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis, MUSCLE NERV, 23(6), 2000, pp. 874-882
Assessment: Prevention of post-lumbar puncture headaches - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Authors: Evans, RW Armon, C Frohman, EM Goodin, DS
Citation: Rw. Evans et al., Assessment: Prevention of post-lumbar puncture headaches - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, NEUROLOGY, 55(7), 2000, pp. 909-914
Inhibitory simple partial (non-convulsive) status epilepticus after intracranial surgery
Authors: Armon, C Radtke, RA Friedman, AH
Citation: C. Armon et al., Inhibitory simple partial (non-convulsive) status epilepticus after intracranial surgery, J NE NE PSY, 69(1), 2000, pp. 18-24
How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
Authors: Armon, C
Citation: C. Armon, How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?, AMYOTROPH L, 1(1), 1999, pp. 3-14
A controlled trial of recombinant methionyl human BDNF in ALS
Authors: Kasarskis, EJ Shefner, JM Miller, R Smith, RA Licht, J Mitsumoto, H Hopkins, LC Rosenfeld, J Pascuzzi, R Cornblath, DR Armon, C Strong, MJ Kula, R Windebank, A Bosch, EP Smith, BE Cashman, N Sivak, M Sergay, S Siddique, T Sufit, RL Johnston, W Brooke, MB Graves, MC Olney, RK Roos, RP Neville, H Ringel, SP Ross, M Bradley, WG Sharma, KR Parry, G Mandler, R Giuliani, M Thornton, CA Jackson, C Bryan, W Bromberg, M Tandan, R Fries, T Phillips, L Brooks, BR Fenichel, G Pestronk, A Bear, M Beatey, R Fuller, C Hill, R Malta, E Nakanishi, A Patel, A Thurmond, B Cedarbaum, JM Stambler, N
Citation: Ej. Kasarskis et al., A controlled trial of recombinant methionyl human BDNF in ALS, NEUROLOGY, 52(7), 1999, pp. 1427-1433
Seizure onset from periventricular nodular heterotopias: Depth-electrode study
Authors: Kothare, SV VanLandingham, K Armon, C Luther, JS Friedman, A Radtke, RA
Citation: Sv. Kothare et al., Seizure onset from periventricular nodular heterotopias: Depth-electrode study, NEUROLOGY, 51(6), 1998, pp. 1723-1727
Linear estimates of rates of disease progression as predictors of survivalin patients with ALS entering clinical trials
Authors: Armon, C Moses, D
Citation: C. Armon et D. Moses, Linear estimates of rates of disease progression as predictors of survivalin patients with ALS entering clinical trials, J NEUR SCI, 160, 1998, pp. S37-S41
Risultati: 1-10 |